S Parke

No ORCID on file · 4 papers in corpus
rct 2026
Efficacy and Safety of Vilaprisan in the Treatment of Uterine Fibroids: Data from ASTEROID 5, a Phase 3 Multicenter Randomized Controlled Trial
Journal of clinical medicine ·doi:10.3390/jcm15093246

Background/Objectives: Vilaprisan and ulipristal acetate (UPA) have demonstrated efficacy in treating uterine fibroids (UFs). However, a direct comparison of vilaprisan and UPA has been restricted, to date, to a small phase 2 study. Here, w…

nonrandomized-trial 2018
Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study

Qi Yu,1 Zirong R Huang,2 Mulan Ren,3 Qing Chang,4 Zhongqi Zhang,5 Susanne Parke61Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China; 2Department of Family Planning, Obstetrics & Gynecology Hospita…

rct 2013
Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study
Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology ·doi:10.3109/01443615.2013.800851

The objective of this multicentre, randomised, double-blind study was to compare a combined oral contraceptive (COC) containing oestradiol valerate/dienogest (E2V/DNG) administered in a dynamic dosing regimen with a monophasic COC containin…

rct 2011
Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial
Human Reproduction ·doi:10.1093/humrep/der224

BACKGROUND: This double-blind trial investigated the efficacy and safety of estradiol valerate/dienogest (E(2)V/DNG) for the treatment of heavy menstrual bleeding without recognizable organic pathology. METHODS: Otherwise healthy women wit…